{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037592","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.415389+00:00","generated_at":"2026-06-12T09:12:48.452316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023","bullets":["Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.","R&D expenses $59.1M, up from $46.7M; G&A $7.6M vs $6.1M.","Cash and securities $207.7M as of June 30, 2023; funds operations through 2024.","Enrollment ongoing in ACHIEVE (DYNE-101, DM1) and DELIVER (DYNE-251, DMD) registrational trials; initial data expected H2 2023.","EMA granted orphan drug designation for DYNE-101 in DM1; FORCE platform CNS delivery data at ASGCT."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037592","json":"https://secwatch.observer/filing/0000950170-23-037592.json","markdown":"https://secwatch.observer/filing/0000950170-23-037592.md","text":"https://secwatch.observer/filing/0000950170-23-037592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/0000950170-23-037592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/dyn-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:12:48.452316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16be82486789818b54bc9479ef126d588983b751","claim":"Dyne Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $64.9 million, EPS $1.08 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended June 30, 2023 was $64.9 million, or $1.08 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/0000950170-23-037592-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$64.9 million"},{"label":"EPS","value":"$1.08 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}